We are very excited to begin our OCRID activities once classes start back up again. The first of our Upcoming OCRID Activities:

- **TB**
  - Delivery strategies are urgently needed. SHetA2 and OHet72 are novel anti-bacterial agents that target specific parts of the cell. Contreras has developed inhalable nanocrystal formulations of SHetA2 and OHet72 for delivery to the alveolar region of the lung, the main place of MTB replication. A guinea pig model will be used for testing the pharmacokinetics, safety and efficacy.

The global control of TB is threatened by an increased number of multi-drug resistant strains. The project aims to control TB by using SHetA2 and OHet72.

Dr. Heather Gappa is pleased to announce that Dr. Lucila Garcia has been selected as a member of the National Academy of Medicine. She will be recognized at the 2020 Annual Meeting.

We would like to give a hearty congratulations to our External Advisory Committee (EAC) member Dr. Bruce Stanton. We had 4 outstanding poster presentations this year. The annual symposium reached over 100 attendees. We look forward to an exciting 2020 symposium!

Below you find some selected achievements from our center investigators. We have made big strides in the field of respiratory and infectious diseases.

- Dr. Adolfo Garcia was elected as a member of the National Academy of Medicine. He will be recognized at the 2020 Annual Meeting.
- Dr. Pushparaj Jeysingh was awarded the National Science Foundation Faculty Early Career Development (CAREER) Program award, NSF Award No. 1943094. The research will focus on developing new therapies for respiratory and infectious diseases.
- Dr. Veronique Lacombe, Phase II project leader, will be elevated to the status of esteemed director, Dr. Lin (2014) is named as director of the Center 2019.
- Matthew Cabeen, Ph.D., is leading the veterinary center.
- Dr. Ashish Ranjan was appointed to the Foundation of the American Physiological Society! Dr. Ranjan (2014) is named as director of the Center 2019.
- We would like to thank all those that attended this year and we invite you to attend next year! Over 90 people came to share their research.
- The Library of Congress Tuneman said that the library has established 140 papers. Particularly impressive is our project/pilot project leader, the development of a new therapy for respiratory and infectious diseases.
- The first year of the Phase II CoBRE funding was an exciting year. OCRID was able to establish 140 papers. Particularly impressive is our project/pilot project leader, the development of a new therapy for respiratory and infectious diseases.